SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting. The 2018 ASH Meeting will be held December 1-4 in San Diego. The rezafungin ASH abstract (2071), titled "Pharmacokinetic-Pharmacodynamic Analyses to Provide Rezafungin Prophylaxis…

Employee feedback places Cidara among top 15 small companies in the area SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it has been named a Top Workplace by The San Diego Union-Tribune for the second consecutive year. Cidara ranked among the top 15 small companies, and the number one ranked biotech in the small company category, in the San Diego Metro Area. "We are once…

SAN DIEGO, Nov. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended September 30, 2018 and provided an update on its corporate activities and product pipeline. "We made considerable progress during the third quarter of 2018 with the initiation of our Phase 3 ReSTORE trial of rezafungin, for the treatment of invasive candida infections, and the granting by the…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting its Cloudbreak™ immunotherapy discovery platform and new antiviral program at the upcoming World Antimicrobial Resistance (AMR) Congress taking place October 25-26, 2018 in Washington, DC. The presentation, titled "Immunobiotics: Cloudbreak Antibody Drug Conjugates (ADC) as countermeasures against multi-drug resistant bacterial infections," is scheduled for 11:10 a.m. Eastern Time on…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of its lead antifungal rezafungin will be presented at the 2018 Hot Topics in Infectious Diseases (HTIDE) Conference to be held in Mestre, Venice from October 25-26, 2018. Rezafungin is the only once-weekly antifungal product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. A total of three rezafungin…

STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara's novel once-weekly antifungal agent SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company's Phase 2 STRIVE trial of rezafungin at IDWeek…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. "Given the…

Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company's prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the…

SAN DIEGO, Sept. 24, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at two upcoming investor conferences. 2018 Cantor Global Healthcare Conference, New York, October 1, 2018 at 9:30 a.m. EDT (6:30 a.m. PDT) Ladenburg Thalmann 2018 Healthcare Conference, New York, October 2, 2018 at 8:30 a.m. EDT (5:30 a.m. PDT)…

Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of industry leader David Gollaher, Ph.D., to the company's Board of Directors. "With more than 30 years of experience in the biopharma and healthcare industry, Dr. Gollaher is an outstanding addition to our Board,"…